Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Final Results

23rd Nov 2005 07:00

International Medical Devices PLC23 November 2005 INTERNATIONAL MEDICAL DEVICES PLC ANNOUNCEMENT OF PRELIMINARY RESULTS FOR THE PERIOD ENDED 31 AUGUST 2005 HIGHLIGHTS • Board delivers on strategy • Acquisitions of Technology Patents and Distribution Rights • Acquisition of a UK distributor • Equity fundraising of £750,000 CHAIRMAN'S STATEMENT On behalf of the Board of International Medical Devices PLC ("IMD"), I ampleased to inform you that IMD has made real progress for the year ended 31stAugust 2005 and beyond. Following admission to AIM on the 10th November 2004, IMD announced on the 24thJune 2005 that the company had conditionally agreed to acquire a range ofTechnology Patents from Eastland Technology Australia Limited ("ETA") andacquired Distribution Rights over a portfolio in excess of 1,200 EastlandMedical Systems Limited ("EMS") products. The consideration for the acquisitionof the Technology Patents was satisfied by the payment of £300,000 in cash andthe issue of 55,160,000 new Ordinary shares to ETA. The consideration for theacquisition of the Distribution Rights was satisfied by the issue of 40,500,000new Ordinary shares to EMS. In addition. £750,000 was raised by way of placingof 12,500,000 new Ordinary shares of 1p each at 6p per share. These transactions were voted on and approved at the Extraordinary GeneralMeeting held on 18th July 2005. In my June 2005 letter to shareholders, I clearly outlined the strategy that isnow being actively implemented. Notably that IMD would seek to make acquisitionsof established medical device distribution businesses in order to provide accessto market for both the EMS product portfolios in the near term, and theexploitation of the ETA patents via the product launch of safe needle productover the next two years. The first acquisition was announced to the exchange on the 19th September 2005.IMD acquired the entire share capital of Meddis Limited, a niche distributor ofacute care medical devises including catheters, wound drainage systems andophthalmic scalpels. Meddis Limited, based in Wallingford, near Oxford employs 8people including a sales force of 5 professionals and supplies both to the NHScentral purchasing and logistics organisation, the Purchasing And Supply Agency(PASA) and direct to hospital trusts with accounts throughout the UK. Thisacquisition cost £400,000 of which £200,000 was issued as new ordinary shares at10p. The acquisition of Meddis Limited represents the first step in IMD's ambition toput in place a European medical device distribution network through which thecompany will sell its portfolio of products in particular the safe needleproduct lines: • "Clip-on"• "Safeline"• "Autoinjecta"• "Reversyringe"• "Retra-lok" This strategy is currently being coined out in Meddis Limited where EMS patentedthorassic drainage products are currently being launched following PASAapproval. The Board is continuing to examine other acquisitions products in line with theIMD strategy and I look forward to announcing further growth in the Company. Results and Dividends The operating loss for the year on all operations was £316,067. No dividend is recommended. Funding In the period the company raised £750,000 in a private placement of 12,500,000Ordinary shares of 1p each at a price of 6p. As at 31st August 2005, cash at Bank was £363,299. Conclusion Having made its first acquisition of an operating medical device distributor,IMD can look forward to an exciting growth phase over the next 12 months. TheBoard remains confident that the market climate for the launch of safe needleproducts is increasingly encouraging the following Unison's recent success inwinning a court case against the Scottish NHS. Unison took a test case,involving two ambulance paramedics, to the court of session in Edinburgh lastyear. Three appeal judges ruled that the NHS in Scotland could not refuse tointroduce safety syringes on cost grounds alone as this breached European Healthand Safety Laws. It is against this background that IMD continues to plan the product launch ofits safe needle portfolio with the next 24 months. Lindsay C. S. Sanford Chairman Monday 21 November 2005 PROFIT AND LOSS ACCOUNT for the period ended 31 August 2005 2005 £ ADMINISTRATION EXPENSES (322,564) OPERATING LOSS (322,564) INTEREST RECEIVABLE 6,497 LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION (316,067) TAXATION ON LOSS ON ORDINARY ACTIVITIES - LOSS ON ORDINARY ACTIVITIES AFTER TAXATION FOR THE FINANCIAL PERIOD (316,067) Loss per ordinary share (0.01249) Diluted loss per ordinary share (0.01248) There were no other gains or losses other than those recognised in the profitand loss account. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS for the period ended 31 August 2005 2005 £ Loss for the financial period (316,067)Issue of share capital 1,244,934Premium on issue 7,577,867Expenses on issue (327,479)Net increase in shareholders' funds 8,179,255Closing shareholders' funds 8,179,255 BALANCE SHEET as at 31 August 2005 2005 £ £ INTANGIBLE ASSETS 7,952,800 CURRENT ASSETSDebtors 128,031Cash at bank and in hand 363,299 491,330 CREDITORS: Amounts falling due within one year (264,875) CURRENT ASSETS 226,455 NET ASSETS 8,179,255 CAPITAL AND RESERVES Share capital 1,244,934Share premium account 7,250,388Profit and loss account (316,067)EQUITY SHAREHOLDERS' FUNDS 8,179,255 CASH FLOW STATEMENT for the period ended 31 August 2005 2005 £ RECONCILIATION OF OPERATING LOSS TO NET CASH FLOW FROM OPERATING ACTIVITIESOperating Loss (322,564)Increase in debtors (128,031)Increase in creditors 264,875NET CASH OUTFLOW FROM OPERATING ACTIVITIES (185,720) RETURNS ON INVESTMENTS AND SERVICING OF FINANCEInterest received 6,497 CAPITAL EXPENDITURE AND FINANCIAL INVESTMENT Purchase of Patents (7,952,800) NET CASH OUTFLOW BEFORE FINANCING (8,132,023) FINANCING Issue of new share capital 8,822,801Expenses on issuing of new share capital (327,479) INCREASE IN CASH IN THE PERIOD 363,299 RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS 2005 £ Movement in cash in period 363,299Net cash at 31 August 2005 363,299 NOTES: 1. The financial information in this announcement does not constitutestatutory accounts as defined in section 240 of the companies Act 1985. Theauditors have given an unqualified report that does note contain any statementunder section 237(2) or (3) of the Companies Act 1985, on the statutory accountsfor the year ended 31 August 2005. 2. Copies of the Company's Report and Accounts will be sent toshareholders shortly and will be available at the registered office of thecompany: 3rd Floor, Windsor House, 55 St James's Street, London SW1A 1LA. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

Intelliam Ai
FTSE 100 Latest
Value10,419.59
Change-33.09